


Long-Acting Injectable Center of Excellence

Long-Acting Injectable (LAI) antipsychotic medications can be a successful treatment option for individuals who have schizophrenia or bipolar disorder. Despite strong evidence for their clinical benefits, there is a low rate of LAI use in the United States.

The Long-Acting Injectable COE provides FREE resources, education, consultation, tools and more on the use of LAIs.



SMI Adviser Long-Acting Injectable Center of Excellence

The Long-Acting Injectable (LAI) Center of Excellence (COE) provides FREE resources, education, consultation, tools and more on the use of LAIs. Let SMI Adviser help you increase and improve the use of LAIs in individuals with schizophrenia and bipolar disorder. The LAI COE is led by SMI Adviser Physician Expert, Alexander Young, MD, MSHS, and SMI Nursing Expert, Donna Rollin, PhD, APRN, and supported by members of the LAI Workgroup: Oliver Freudeneich, MD, Sarah MacLaurin, PMHNP, Jon Medina, PMHNP, Robert Cotes, MD, and Leon Ravin, MD.

For individual and family resources on using long-acting injectables, visit the individual and family Knowledge Base.



FREE CME/NCPD-certified online courses. Direct access to LAI activities and upcoming events.

Sign up for the Clozapine and LAI COE Exchange listserv. Share best practices with other clinicians. Join the conversation.




Resources on Long-Acting Injectables

Browse resources and find answers from the SMI Adviser Knowledge Base

- TIPS ON STARTING OR SWITCHING LAIS +
- TIPS ON ADMINISTRATION AND MONITORING +
- MANAGEMENT OF SIDE EFFECTS +
- TIPS ON CHALLENGES +
- PATIENT/FAMILY INFORMATION AND HANDOUTS +



Find answers. Access clinical tips that provide information on starting LAIs, managing side effects, working through challenges, and more. Quick links to tips, tools and evidence-based data.



Request a Consultation

Our clinical experts can answer questions about SMI from all mental health clinicians. Ask us about psychopharmacology, therapies, recovery supports, patient and family engagement, education, and much more.

[SUBMIT NOW](#)

www.smiadviser.org/submit-consult



Request a FREE confidential consultation. Ask us about prescribing LAIs, therapeutic drug monitoring, facts about formulations, management of side effects, and other issues.

REQUEST A FREE CONSULTATION

Let SMI Adviser help you increase and improve the use of LAIs in individuals with schizophrenia and bipolar disorder.

For one-stop access to evidence-based answers, visit www.SMIadviser.org/LAI

GRANT STATEMENT

Funding for this initiative was made possible (in part) by Grant No. 1H795M080818-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.